Flunixin Meglumine Injectable Solution (Im, Iv) Suppliers & Bulk Manufacturers
Available Forms: Injectable solution (IM, IV)
Available Strengths: 100 mg/mL
Reference Brands: Banamine (US)
Category:
Veterinary Product
Flunixin Meglumine injection is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis. It effectively relieves pain, inflammation, and fever in animals. Benefits include rapid pain relief, decreased inflammation, and improved comfort in livestock and horses, supporting animal health and productivity.
Flunixin Meglumine Injectable solution (IM, IV) is available in Injectable solution (IM, IV)
and strengths such as 100 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Flunixin Meglumine Injectable solution (IM, IV) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Flunixin Meglumine Injectable solution (IM, IV) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Flunixin Meglumine injection is approved in both the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in line with GMP and IVDR standards. In the US, FDA approval involves comprehensive clinical data and safety evaluations, mainly for pain and inflammation in horses, livestock, and pigs. In the EU, CE marking certifies conformity with veterinary medicinal regulations. These products undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical trial results, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective flunixin meglumine formulations worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing